ロード中...
Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
Hepatitis C virus (HCV) genotype 3 is responsible for 30.1% of chronic hepatitis C infection cases worldwide. In the era of direct-acting antivirals, these patients have become one of the most challenging to treat, due to fewer effective drug options, higher risk of developing cirrhosis and hepatoce...
保存先:
| 出版年: | Braz J Med Biol Res |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Associação Brasileira de Divulgação Científica
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5089232/ https://ncbi.nlm.nih.gov/pubmed/27783808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1590/1414-431X20165504 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|